Skip survey header

ACTION Symposium Registration Page

Time for ACTION:
How to Overcome the Barriers to Effective Obesity Care

A Corporate Symposium where experts in the field will discuss findings from the ACTION study and collaborative efforts to enhance access to effective obesity care.

The ACTION study is the first nationwide US study to investigate barriers in obesity management from multiple perspectives.


Wednesday, November 1, 2017
Gaylord National Resort & Convention Center
Woodrow Wilson A
National Harbor, MD

Agenda

6:45 PM Dinner Served/Registration
7:00 PM Welcome and Introduction
7:15 PM Scientific Presentation  
8:35 PM Question and Answer Session
Dinner will be served.a


To register your interest in this Corporate Symposium please click Next to continue. Thank you.

This program is sponsored by Novo Nordisk.
This is a sponsored education presentation; it will not be certified for continuing medical education credit.

aDue to certain state laws and regulations, if you: (1) have a license to provide health care in Minnesota or Vermont or (2) are a member of a Medication Advisory Committee in the District of Columbia, please do not partake in any food and/or beverages available at this program. We appreciate your understanding and apologize for any inconvenience this may cause.
 

In accordance with the PhRMA Code on Interactions with Healthcare Professionals, attendance at this
 

The content of this educational program is limited to health care professionals. Accordingly, attendance by guests or spouses is not appropriate and cannot be accommodated.
 

Corporate Symposium and opinions expressed by the presenters are those of the sponsor and not those of The Obesity Society and the American Society for Metabolic and Bariatric Surgery.

This dinner and the content of the Corporate Symposium are the sole responsibility of Novo Nordisk Inc.

If you experience any issues with registration, please contact the Technical Help Desk at CBhelpdesk@clinicalbridges.com.
Novo Nordisk is a registered trademark of Novo Nordisk A/S.